SynthesisProstate cancer and prostatic diseases2011
IL-10 polymorphisms and prostate cancer risk: a meta-analysis.
Synthesis in Prostate cancer and prostatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies.Oncotarget · 2017Pooled it
- The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls.Omics : a journal of integrative biology · 2013Pooled it
- XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis.Prostate cancer and prostatic diseases · 2011Pooled it
- Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.The Prostate · 2015Trial
- Puerarin as a multifaceted anticancer agent: Mechanisms, targets, and therapeutic potential across multiple cancers.Chinese herbal medicines · 2026Review
- Review
- Identification of crucial genes involved in thyroid cancer development.Journal of the Egyptian National Cancer Institute · 2023Review
- Alcohol and Prostate Cancer: Time to Draw Conclusions.Biomolecules · 2022Review
- The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.Exploration of targeted anti-tumor therapy · 2022Review
- A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.Frontiers in oncology · 2022Article
- Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy.The international journal of biochemistry & cell biology · 2020Review
- Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer.Cancers · 2019Review
- Association of SNPs/haplotypes in promoter of TNF A and IL-10 gene together with life style factors in prostate cancer progression in Indian population.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Article
- Article
- Genetic polymorphisms of IL-6 and IL-10 genes correlate with lung cancer in never-smoking Han population in China.International journal of clinical and experimental medicine · 2015Article
- Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer.Molecular biology reports · 2014Article
- Genetic factors regulating inflammation and DNA methylation associated with prostate cancer.Prostate cancer and prostatic diseases · 2013Article
- Gene variants in the angiogenesis pathway and prostate cancer.Carcinogenesis · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence is accumulating that chronic inflammation may have an important role in prostate cancer (PCa). Three common polymorphisms in the promoter of interleukin-10 (IL-10) gene, -1082 A>G, -819 C>T and -592 C>A, have been implicated to alter the risk of PCa, but the results of relative studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed an updated meta-analysis on the basis of 10 studies. A comprehensive search was conducted to examine all the eligible studies of IL-10 polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) give a sense of the precision of the estimate. Overall, there were no significant associations between increased risk of PCa and IL-10 -1082 A>G, -819 C>T and -592 C>A polymorphisms. However, meta-analysis suggested that IL-10 -819 C>T and -592 C>A polymorphisms might be modestly associated with PCa aggressiveness (T versus C, OR=1.162, 95% CI: 1.035-1.305, P=0.011; A versus C, OR=1.131, 95% CI: 1.012-1.264, P=0.030; respectively). IL-10 -819 C>T and -592 C>A polymorphisms might impact PCa progression. Variant alleles at both -819 and -592 were modestly associated with advanced stages of PCa. Additional well-designed studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.